Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Gemcitabine (Primary) ; Ribociclib (Primary) ; Sonidegib (Primary) ; Trametinib (Primary) ; Filgrastim; Pegfilgrastim
- Indications Anaplastic astrocytoma; Brain cancer; CNS cancer; Ependymoma; Glioblastoma; Glioma; Medulloblastoma; Oligodendroglioma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms SJDAWN
- 01 Mar 2018 Status changed from not yet recruiting to recruiting.
- 20 Feb 2018 Planned initiation date changed from 1 Apr 2023 to 1 Mar 2018.
- 19 Feb 2018 New trial record